

ARECOR GRANTED KEY US PATENT

Building a robust global patent portfolio for its Arestat™ platform

Cambridge, UK., 13 May 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the grant by the United States Patent and Trademark Office of U.S. Utility Patent No. 10,925,965 B2, a patent that contributes to the Company’s global patent portfolio underpinning its Arestat™ technology platform. This US patent claims proprietary formulation technology aimed at enabling stabilised multi-dose protein products that are desirable in the market but often challenging to achieve. The US is an important international market for biopharmaceuticals and one where Arecor has established a number of key commercial and development partnerships.

Dr Jan Jezek, Chief Scientific officer of Arecor, said: “The grant of this US patent is an important milestone in our rapidly growing Arestat™ patent portfolio. We have been very successful in innovating and patenting unique combinations of excipients that impart considerably improved stability for protein and peptide based therapeutics and vaccines. This new patent applies particularly to enabling multi-dose compositions that are becoming increasingly popular, particularly in injection pen formats, delivering convenience of use, especially for self-administration, and offering potential improvements to treatment adherence. The patent considerably strengthens our intellectual property portfolio and our position as a leader in the formulation of enhanced therapeutics and vaccines.”

An increasing number of therapeutic and vaccine products are presented as multi-dose compositions. The most widely used multi-dose products are injection pens that are filled with sufficient therapeutic product for multiple administration doses. Rather than preparing a new dose for each administration using a vial or syringe, the user can carry a pre-filled injection pen, for example for one month, and self-administer a very simple injection as needed. A second type of multi-dose product is vaccines for large scale deployment, for example in the case of pandemic situations. Such vaccines are conveniently filled as multi-dose vials allowing multiple patients to be vaccinated efficiently in a short period of time.

-ENDS-

For more information, please contact:

Areacor Limited

www.arecor.com

Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com

Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com

Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com

Consilium Strategic Communications

Chris Gardner, David Daley, Angela Gray Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com

Notes to Editors

About Areacor

Areacor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using its Arestat™ technology, the Company is developing a broad portfolio of therapies both through its proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Its treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

For further details please see our website, www.arecor.com